Company news
Chiome Bioscience Inc. news in 2022
Chiome Bioscience Inc.'s news releases, calls and decks from 2022, newest first.
Announcement of target-specific research and option agreement with Heidelberg Pharma
July 13, 2022
Service agreement with option contract with Rohto Pharmaceutical Co., Ltd.
July 11, 2022
First patient in of cancer therapeutic antibody CBA-1535 in a Phase 1 clinical trial
July 4, 2022
Conclusion of contract with additional institutes and first dosing of CBA-1205 in the second part of Phase 1 study
June 13, 2022
Submission of the application for a Phase I study of CBA-1535
February 16, 2022
License agreement for a diagnostic kit with Fujirebio, Inc.
February 15, 2022
Supplementary Information for Financial Results FY12/21
February 14, 2022
Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2021
February 14, 2022